Lung Fung Group Holdings Limited Annual Report 2025/2026 – Key Investor Insights
Executive Summary
Lung Fung Group Holdings Limited (“Lung Fung” or “the Company”) has published its inaugural annual report following its Main Board listing on the Hong Kong Stock Exchange on 5 June 2026. The report reveals a robust operational foundation, strong financial performance, and a clear commitment to shareholder value, including a newly stated dividend policy. Investors should note several key developments, financial highlights, and governance practices that may significantly impact share value.
Key Financial Highlights
- Profit for FY2026: HK\$269.1 million, up from HK\$170.4 million in FY2025.
- Core Net Profit (Non-HKFRS): HK\$300.9 million, up from HK\$223.9 million in FY2025, adjusted to exclude investment property fair value decreases and listing expenses.
- Pro-forma Core Earnings Per Share: HK\$0.60, based on 500 million shares post-listing.
- Net Gearing Ratio: Dramatically reduced from 1,566.8% in FY2025 to 1,046.4% in FY2026, with expectations to drop near zero post-listing due to capital raised.
- Net proceeds from IPO: HK\$599.6 million, not yet utilized as of report date, deposited in short-term interest-bearing accounts.
Dividend Policy – Major Change
- No final dividend recommended for FY2026.
- New Commitment: From FY2027 (first full financial year post-listing), Lung Fung intends to distribute not less than 60% of distributable profits as dividends to shareholders, subject to operational, financial, and strategic considerations.
- This is a substantial, market-moving commitment, signaling management confidence in sustained earnings and cash flow, likely to impact share price positively.
Material Events Post-Reporting Period
- Capitalization Issue: On 18 May 2026, 374 million shares issued to shareholders via share premium capitalization, strengthening equity base.
- Dividend Declaration: On 21 May 2026, HK\$23 million dividends declared and settled by offsetting amounts due from related parties.
- Global Offering: 125 million new shares issued at HK\$5.18 per share.
- All outstanding related party balances were settled before listing.
Operational and Strategic Review
- Business Model: Focused on the sales of beauty, health, pharmaceutical, and consumer products under the “Lung Fung” brand.
- Customer Base: Highly diversified, no reliance on any single customer; risk profile mainly tied to general consumer demand and retail market trends.
- Competitive Landscape: Operates in a highly competitive market, facing both offline and online rivals. Key competitive strengths include product mix, pricing, retail network, and supply chain capabilities.
- Risk Factors: Exposure to market demand fluctuations, competitive pricing pressures, and operational risks. No single customer or supplier accounts for more than 30% of purchases or sales.
Corporate Governance and Risk Management
- High governance standards: Full compliance with CG Code except for C.2.1 (explained in report).
- Anti-corruption and whistle-blowing policies: Robust policies in place, regularly reviewed and updated. No suspicious whistle-blowing activities reported.
- Risk Management: Internal control systems reviewed by independent consultants; remedial actions taken. Audit Committee actively monitors risk and internal controls.
- Disclosure of Inside Information: Strict disclosure policies, timely communication via reports, announcements, and website.
Financial Instruments and Risk Exposures
- Liquidity: Net current liabilities as of 31 March 2026, but post-listing liquidity improved significantly with IPO proceeds.
- Currency and Interest Rate Risks: Some exposure to USD, JPY, RMB, but impacts are minor. Interest rate risk managed via floating-rate borrowings.
- Credit Risk: Well-managed, internal grading system; no material credit events reported.
- Capital Structure: Management reviews and balances capital via dividends, new share issues, and debt management.
Related Party Transactions and Compliance
- No material related party transactions post-listing, except for fully exempted de minimis transactions.
- All property leasing agreements with related parties are treated as one-off capital asset acquisitions, not classified as continuing connected transactions under HKEX rules.
- No outstanding treasury shares, equity-linked agreements, or material contracts involving directors or controlling shareholders.
Shareholder Communication and Rights
- Shareholder proposals can be submitted for discussion at AGMs/EGMs; procedures clearly outlined.
- Communication policy ensures equal, timely access to information.
Environmental, Social and Governance (ESG)
- Practical measures implemented for energy saving, waste reduction, and paper reduction.
- Ongoing review and enhancement of environmental practices.
Summary – Price Sensitive Points for Investors
- Dividend Policy Shift: Lung Fung’s commitment to distributing not less than 60% of distributable profits from FY2027 is a strong signal of shareholder value and financial stability, likely to support share price appreciation.
- Post-IPO Liquidity: HK\$599.6 million net proceeds, not yet deployed, provide a substantial buffer for expansion, debt reduction, or dividend payouts.
- Material Settlements: All related party balances cleared before listing, ensuring clean balance sheet and regulatory compliance.
- Solid Financial Performance: Significant profit growth, reduced gearing, and strong cash flow positions Lung Fung as a stable, growth-oriented investment.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information is based on publicly available documents and may be subject to change.
龍豐集團控股有限公司2025/2026年報 – 投資者重點（廣東話版）
執行摘要
龍豐集團控股有限公司（「龍豐」或「公司」）已於2026年6月5日登陸香港聯交所主板，並發表首份年報。報告顯示公司營運基礎穩健，財務表現強勁，並明確承諾股東價值，尤其是新訂股息政策。投資者需注意多項重要發展、財務重點及管治措施，這些均可能顯著影響股份價值。
財務摘要
- 2026財年盈利：2.691億港元（較2025年增長）
- 核心純利（非香港財務報告準則）：3.009億港元（排除物業公平值減少及上市開支）
- 備考核心每股盈利：0.60港元（以上市後5億股份計算）
- 淨資產負債比率：由2025年1,566.8%降至2026年1,046.4%，上市後預期接近零
- IPO所得淨額：5.996億港元，報告期內尚未動用
股息政策重大改變
- 2026財年不派末期股息。
- 新承諾：自2027財年（上市後首個完整財年）起，龍豐擬派發不少於可分派溢利60%的股息，視乎營運、財務及策略考量。
- 此舉展現管理層對持續盈利及現金流的信心，極可能正面刺激股價。
報告期後重大事件
- 資本化發行：2026年5月18日發行3.74億股，增強資本基礎。
- 股息宣派：2026年5月21日宣派2,300萬港元股息，以與關聯方款項抵銷。
- 全球發售：發行1.25億新股，每股5.18港元。
- 上市前所有關聯方結餘已清零。
營運及策略回顧
- 業務模式：以「龍豐」品牌銷售美妝、保健、藥品及消費品。
- 客戶基礎：多元化，無單一客戶依賴，風險主要來自整體消費需求及零售市場。
- 競爭環境：市場競爭激烈，線下線上皆有對手。產品組合、定價、零售網絡及供應鏈為競爭優勢。
- 風險因素：市場需求波動、價格壓力、營運風險。無單一客戶或供應商佔採購/銷售超過30%。
企業管治及風險管理
- 高管治標準：除C.2.1外全面遵守企業管治守則。
- 反貪污及舉報政策：制度完善，定期檢討，無可疑舉報活動。
- 風險管理：內控系統經獨立顧問審查，已採取補救措施。審核委員會積極監控。
- 內幕消息披露：嚴格政策，及時公佈。
金融工具及風險敞口
- 流動性：2026年3月31日流動負債淨額，但上市後流動資金大幅改善。
- 貨幣及利率風險：部分美元、日圓、人民幣敞口，影響屬輕微。利率風險以浮息借款管理。
- 信貸風險：內部分級系統管理，無重大信貸事件。
- 資本結構：管理層通過股息、新股發行及債務管理平衡資本。
關聯方交易及合規
- 上市後無重大關聯方交易，僅豁免微不足道交易。
- 與關聯方物業租賃協議屬一次性資本資產收購，無持續關聯交易。
- 無庫存股份、股票掛鈎協議或董事╱控股股東重大合約。
股東溝通及權利
- 股東可提出建議於股東大會討論，程序清晰。
- 溝通政策保障資訊平等及及時。
環境、社會及管治（ESG）
- 已實施節能、減紙及廢物管理措施，持續檢討提升。
總結 – 影響股價的重點
- 股息政策重大轉變：承諾自2027財年起派發不少於可分派溢利60%，強烈信號支持股價。
- IPO後流動資金：近6億港元未動用，為擴張、減債或派息提供強大資金緩衝。
- 重大結算：上市前所有關聯方結餘已清零，財務狀況潔淨合規。
- 財務表現穩健：盈利增長、負債減少、現金流強，龍豐定位穩健成長型投資。
免責聲明
本文僅供資訊參考，並非投資建議。投資者應自行進行盡職調查及諮詢專業人士再作投資決定。資料來源於公開文件，可能隨時變動。
